Table 1.

Subject Demographics and Metabolic Characteristics

Group	NGT	IGT	T2D	P (ANOVA)
Female/male	34/28	19/6	8/4	.156
Age, y	40 ± 12	45 ± 13	49 ± 11a	.023
BMI, kg/m2	28.6 ± 5.8	31.0 ± 8.6	32.3 ± 8.7	.143
Systolic BP, mm Hg	116 ± 14	124 ± 14a	129 ± 18b	.007
Diastolic BP, mm Hg	74 ± 9	77 ± 7	82 ± 10b	.023
Total cholesterol, mg/dL [mmol/L]	179 ± 35 [4.6 ± 0.9]	187 ± 28 [4.8 ± 0.7]	166 ± 29 [4.3 ± 0.8]	.19
LDL cholesterol, mg/dL [mmol/L]	117 ± 35 [3.0 ± 0.9]	121 ± 34 [3.1 ± 0.9]	115 ± 39 [3.0 ± 1.0]	.88
HDL cholesterol, mg/dL [mmol/L]	46 ± 12 [1.2 ± 0.3]	49 ± 12 [1.3 ± 0.3]	38 ± 9 [1.0 ± 0.2]a,d	.018
Triglycerides, mg/dL [mmol/L]	98 ± 62 [1.1 ± 0.7]	118 ± 76 [1.3 ± 0.9]	125 ± 61 [1.4 ± 0.7]	.248
ALT, U/L	26 ± 16	24 ± 9	33 ± 30	.884
AST, U/L	26 ± 10	25 ± 7	27 ± 15	.311
Liver disease index (ANI)	−6.8 ± 0.7	−9.1 ± 1.4	−8.3 ± 1.8	.273
HbA1c, %	5.3 ± 0.3	5.5 ± 0.3	6.2 ± 0.8c,e	<.001
Fasting glucose, mg/dL [mmol/L]	93 ± 7 [5.2 ± 0.4]	96 ± 8 [5.3 ± 0.4]	115 ± 17 [6.4 ± 0.9]c,e	<.0001
120-minute glucose, mg/dL [mmol/L]	109 ± 21 [6.1 ± 1.2]	164 ± 20 [9.1 ± 1.1]c	240 ± 25 [13.3 ± 1.4]c,e	<.0001
Fasting insulin, μU/mL [pmol/L]	9.3 ± 5.8 [65 ± 40]	13.3 ± 8.1 [92 ± 56]b	21.9 ± 20.5 [152 ± 142]c,d	.0001
HOMA-IR	2.2 ± 1.4	3.3 ± 2.1	6.7 ± 6.7c,d	<.0001
Disposition index (oral)	0.15 ± 0.12	0.08 ± 0.06b	0.04 ± 0.05b	<.001

Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; ANI, alcoholic liver disease/nonalcoholic fatty liver disease index. Demographic data of our cross-sectional study cohort (n = 99) of consecutive subjects undergoing an OGTT: mean ± SD.

^aP < .05 vs NGT.

^bP < .01 vs NGT.

^cP < .001 vs NGT.

^dP < .01 vs IGT.

^eP < .001 vs IGT.